GammaCan International to Present IgG-Based Melanoma Program at the 14th Annual BioPartnering Europe Conference
October 05 2006 - 6:30AM
Business Wire
GammaCan International, Inc. (OTC BB: GCAN), a developer of
immunotherapies for the treatment of cancer and other diseases,
today announced that Patrick Schnegelsberg, Chief Executive
Officer, is scheduled to present VitiGam, GammaCan's second
generation product under development for the treatment of melanoma,
to the investor, biotechnology and pharma community at the
BioPartnering Europe Conference. The conference will be held at the
Queen Elizabeth II Conference Centre in London from October 8-11,
2006. Mr. Schnegelsberg is scheduled to present on Monday, October
9th at 12 Noon GMT. About VitiGam: VitiGam is GammaCan's second
generation intravenous IgG-based product and a first-in-class
anti-cancer immunotherapy. GammaCan plans on having VitiGam to
enter phase I/II testing under a US IND in the near future after it
recently held a pre-IND meeting with the FDA. VitiGam is being
designed to target metastatic melanoma patients with Stage III and
IV melanoma. VitiGam is an IgG product that is different from
standard IgGs: It is manufactured from the plasma of donors with
vitiligo, a benign autoimmune skin condition affecting up to 2% of
the general population. GammaCan scientists have shown that this
"enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma
activity in both in vitro and mouse xenograft melanoma models.
Thus, GammaCan expects VitiGam to provide (1) anti-melanoma
activity directed specifically against malignant melanoma cells and
(2) non-specific anti-cancer activity - as is the case with IgG in
general. About GammaCan GammaCan is focusing on the
commercialization of an innovative anti-cancer immunotherapy to
treat metastatic cancer. GammaCan's platform is based on IgG, a
safe, relatively non-toxic human plasma-based product, currently
used to treat a variety of immune deficiencies and autoimmune
diseases. IgG works by strengthening the patient's immune system.
Many experts currently view immunotherapy as a future alternative
to today's standard chemotherapy. GammaCan is developing VitiGam,
its second generation program. VitiGam is an IgG derived from the
plasma of vitiligo donors and is being developed to treat malignant
melanoma. GammaCan owns, and has applied for US patent protection
covering the use of IgG and vitiligo-derived IgG (VitiGam). For
more information about GammaCan visit www.GammaCan.com or call the
company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America). Safe Harbor
Statement: Statements in this document that are not purely
historical are forward-looking statements. Forward-looking
statements in this release include statements regarding the
commercialization of an anti-cancer immunotherapy and the Company
developing the boosting of cancer patients' immune systems with IgG
into an effective treatment. Actual outcomes and the Company's
actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology,
unforeseen technical difficulties in developing the technology, the
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable
for consumers, inability to market the product we produce, among
other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further
risk factors see the risk factors associated with other early state
medical research and development companies filed with the SEC on
Edgar. GammaCan International, Inc. (OTC BB: GCAN), a developer of
immunotherapies for the treatment of cancer and other diseases,
today announced that Patrick Schnegelsberg, Chief Executive
Officer, is scheduled to present VitiGam, GammaCan's second
generation product under development for the treatment of melanoma,
to the investor, biotechnology and pharma community at the
BioPartnering Europe Conference. The conference will be held at the
Queen Elizabeth II Conference Centre in London from October 8-11,
2006. Mr. Schnegelsberg is scheduled to present on Monday, October
9th at 12 Noon GMT. About VitiGam: VitiGam is GammaCan's second
generation intravenous IgG-based product and a first-in-class
anti-cancer immunotherapy. GammaCan plans on having VitiGam to
enter phase I/II testing under a US IND in the near future after it
recently held a pre-IND meeting with the FDA. VitiGam is being
designed to target metastatic melanoma patients with Stage III and
IV melanoma. VitiGam is an IgG product that is different from
standard IgGs: It is manufactured from the plasma of donors with
vitiligo, a benign autoimmune skin condition affecting up to 2% of
the general population. GammaCan scientists have shown that this
"enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma
activity in both in vitro and mouse xenograft melanoma models.
Thus, GammaCan expects VitiGam to provide (1) anti-melanoma
activity directed specifically against malignant melanoma cells and
(2) non-specific anti-cancer activity - as is the case with IgG in
general. About GammaCan GammaCan is focusing on the
commercialization of an innovative anti-cancer immunotherapy to
treat metastatic cancer. GammaCan's platform is based on IgG, a
safe, relatively non-toxic human plasma-based product, currently
used to treat a variety of immune deficiencies and autoimmune
diseases. IgG works by strengthening the patient's immune system.
Many experts currently view immunotherapy as a future alternative
to today's standard chemotherapy. GammaCan is developing VitiGam,
its second generation program. VitiGam is an IgG derived from the
plasma of vitiligo donors and is being developed to treat malignant
melanoma. GammaCan owns, and has applied for US patent protection
covering the use of IgG and vitiligo-derived IgG (VitiGam). For
more information about GammaCan visit www.GammaCan.com or call the
company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America). Safe Harbor
Statement: Statements in this document that are not purely
historical are forward-looking statements. Forward-looking
statements in this release include statements regarding the
commercialization of an anti-cancer immunotherapy and the Company
developing the boosting of cancer patients' immune systems with IgG
into an effective treatment. Actual outcomes and the Company's
actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology,
unforeseen technical difficulties in developing the technology, the
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable
for consumers, inability to market the product we produce, among
other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further
risk factors see the risk factors associated with other early state
medical research and development companies filed with the SEC on
Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024